Conferences
Conferences
Advertisement
Cecilia BrownConferences | February 28, 2024
New adverse drug reactions appeared in the updated labels of 94% of the agents evaluated.
Read More
Cecilia BrownConferences | February 27, 2024
New research highlights the importance of monitoring for interactions between oral anticancer drugs and other therapies.
Mary Mansour Riwes, DOConferences | February 27, 2024
Mary Mansour Riwes, DO, explains what she saw as the important news in GVHD at the 2024 Tandem Meetings.
Cecilia BrownConferences | February 27, 2024
Researchers used a deep learning software to measure muscle, fat, subcutaneous fat, and visceral fat in 3D scans.
Cecilia BrownConferences | February 26, 2024
Cancers of unknown primary pose a “significant challenge due to poor clinical outcomes and limited treatment options."
Mary Mansour Riwes, DOConferences | February 26, 2024
Mary Mansour Riwes, DO, speaks about research on the topic that she presented at the 2024 Tandem Meetings.
Cecilia BrownConferences | February 26, 2024
High-dose PTCy is the “standard of care" for certain patients but the “optimal dosing of PTCy has not been defined."
Cecilia BrownConferences | February 24, 2024
The 3-year follow-up analysis included 152 patients with cGVHD who received 2-5 prior lines of systemic therapy.
Stephanie J. Lee, MD, MPHConferences | February 23, 2024
Stephanie J. Lee, MD, MPH, speaks about what she sees as the key GVHD highlights at the Tandem Meetings.
Cecilia BrownConferences | February 23, 2024
Contrast-enhanced ultrasonography is a noninvasive method that "could contribute to GVHD diagnosis and management guidance."
Cecilia BrownConferences | February 23, 2024
The study showed a certain type of aGVHD is the predominant form that occurs after PTCy-based prophylaxis.
Cecilia BrownConferences | February 23, 2024
The randomized, double-blind trial evaluated the efficacy and safety of ruxolitinib 1.5% cream.
Cecilia BrownConferences | February 23, 2024
The current diagnostic criteria for CNS GVHD “does not cover a majority of cases with strong clinical suspicion."
Stephanie J. Lee, MD, MPHConferences | February 24, 2024
Dr. Lee speaks about study evaluating belumosudil in cGVHD and highlights the critical role of nurses in GVHD care.
Cecilia BrownConferences | February 22, 2024
The phase III BMT CTN 1301 trial evaluated CNI-free strategies using T-cell depletion without additional immune suppression.
Cecilia BrownConferences | February 22, 2024
A team implemented a database that obtained “near real-time” information on GVHD-related telehealth visits.
Cecilia BrownConferences | February 22, 2024
The combination was “exceptionally potent in diminishing” aGVHD, but there was 1 risk factor for developing aGVHD.
Cecilia BrownConferences | February 22, 2024
The off-the-shelf allogeneic CAR-T product is under development for the treatment of relapsed or refractory T-cell ALL/LBL.
Cecilia BrownConferences | February 21, 2024
Orca-T uses "highly purified, polyclonal donor regulatory T cells to control alloreactive immune responses."
Cecilia BrownConferences | February 23, 2024
Researchers aimed to clarify “varying results” from previous research on the relationship between obesity and HSCT ...
Advertisement
Advertisement
Advertisement